⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 4, 2024Open Access

Supplementary Figure S8 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus

Chun‐Ping Chang Teng‐Kuang Yeh Chiung‐Tong Chen Wan-Ping Wang Yen-Ting Chen Chia‐Hua Tsai Yan-Fu Chen Yi‐Yu Ke Jing-Ya Wang Ching-Ping Chen Tsung-Chih Hsieh Mine-Hsine Wu Chen‐Lung Huang Ya-Ping Chen Hong Zhuang Ya‐Hui Chi

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S8. Tissue distribution of DBPR728 and its active moiety 6K465. LC-MS/MS quantification for the concentrations of DBPR728 and 6K465 in tissues (plasma, heart, aorta, liver, lung and kidney) of ICR mice (n = 7) after 24 hr of taking one 300 mpk dose of DBPR728. Errors are mean ± SD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chang et al. (2024) studied this question.

synapsesocial.com/papers/68e664bab6db6435875f1520 https://doi.org/10.1158/1535-7163.25964770.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S8 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
2Supplementary Figure S3 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
3Supplementary Figure S3 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
4Supplementary Figure S4 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
5Supplementary Figure S4 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024

More related papers

Supplementary Figure S5 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
Supplementary Figure S5 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
Supplementary Figure S6 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024